NVCR:NASDAQ, NovoCure Limited

NVCR stock overview

NovoCure Limited (NVCR:NASDAQ) closed at $14.40 on October 26, 2026, down 1.91% on the day. The stock trades 32.9% below its 52-week high of $21.45 and 46.6% above its 52-week low of $9.82. Over the past year, it gained 6.0%. NovoCure Limited is part of the Health Care sector (Medical/Dental Instruments).

Key figures

Price: $14.40
Day change: -1.91%
Volume: 1,166,269
Average volume: 1,337,092
Market cap: 1B+
52-week range: $9.82 – $21.45
50-day average: $16.15
200-day average: $14.82

Price action over the past year

In 252 trading sessions since October 24, 2025, NVCR closed higher on 115 days (46%). Its best day was July 23, 2026 (+28.39%) and its worst was June 18, 2026 (-20.00%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 5 times.

Recent signals

Oct 26, 2026: Trading sideways between $13.84 and $15.71 over 14 days (Sideways scanner)
Oct 10, 2026: News catalyst: Biotech (News Catalysts scanner)

NVCR news

Oct 21, 2026: Novocure Must Show Its Breakout Second Quarter Was A Trend, Not A One-Off
Oct 10, 2026: The Bull Case For NovoCure (NVCR) Could Change Following Japan's Optune Pax Pancreatic Cancer Approval
Oct 1, 2026: Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Oct 1, 2026: Novocures Optune Pax Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Oct 1, 2026: Novocure to Report Third Quarter 2026 Financial Results
Sep 23, 2026: NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall
Sep 23, 2026: NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change
Sep 18, 2026: NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

About NovoCure Limited

NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.

Similar stocks

Find more stocks like NVCR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.